David Mobley Receives $2M from National Institutes of Health to Develop Computational Tools for Drug Discovery

David Mobley received $2M in funding from the National Institute of General Medical Sciences which will support advancing computational methods to guide early stage pharmaceutical drug discovery over the next five years.

The Mobley Lab focuses on developing and using computational tools to dramatically accelerate pharmaceutical drug discovery. The lab focuses on the interface between methods and applications and invest in assessing and improving computational methods as well as applying methods directly in discovery.

“Our vision is to make modeling a tool which plays a key role guiding drug discovery research,” says Mobley. “In particular, we want researchers – ranging from medicinal chemists to structural biologists as well as experts in computation – to routinely input their latest results and ideas into their computer at the end of the workday and return to work to find prioritized next steps for their research.”

Over the next five years, the Mobley Lab plans to develop an increasingly automated pipeline for iterated compound screening, design, and optimization which would dramatically accelerated discovery pipeline, saving time, money, and resources. “We’re excited to advance the frontiers of computer modeling for pharmaceutical drug design,” says Mobley. “This grant will help us continue to improve the accuracy of computational methods, while working more closely to begin using our methods to directly impact and accelerate early-stage drug discovery work.”